Global /South Korea /Healthcare /Drug Manufacturers - General /388870

Pharos iBio Co., Ltd.

388870

• KRX: 388870 • Delayed

9,420KRW 0.7%

6.17 USD

As of 13 June 2026, Pharos iBio Co., Ltd. has a market cap of $80.19M USD, ranking #27118 globally and #1383 in South Korea. It ranks #2433 in the Healthcare sector, and #878 in the Drug Manufacturers - General industry.

Global Rank

27118

Country Rank

1383

Sector Rank

2433

Industry Rank

878

Key Stats

Market Cap

$80.19MUSD

121.95B KRW

Enterprise Value

$68.07MUSD

103.88B KRW

EBITDA (TTM)

-$6.99MUSD

-10.67B KRW

Net Income (TTM)

-$7.07MUSD

-10.76B KRW

PB Ratio

8.8

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jeong Hyeok Yoon open_in_new

Founded

2016

Website

pharosibio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.7%	-1%	-10%	-6.9%	73%	-0.4%	40%	-51%	-51%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	388870 주식회사 파로스아이바이오 ISIN: KR7388870008 Shares Out.: Shares Outstanding: 12.946M¹ Shares Float: 8.656M² TV: TradingView: KRX: 388870 SA: Stock Analysis: KRX: 388870 YF: Yahoo Finance: 388870.KS GF: Google Finance: KRX: 388870 BA: Barron's: 388870 MS: Morningstar: XKRX: 388870	9,420 KRW	TV: TradingView: KRX: 388870 SA: Stock Analysis: KRX: 388870 YF: Yahoo Finance: 388870.KS GF: Google Finance: KRX: 388870 BA: Barron's: 388870 MS: Morningstar: XKRX: 388870

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Pharos iBio Co., Ltd.

Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.15B 13.91T KRW 11K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.77B 10.3T KRW 8K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.24B 7.97T KRW 6K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.96B 7.55T KRW 6K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.55B 6.92T KRW 6K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.44B 6.76T KRW 5K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 950K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 682K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 450K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 401K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 360K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 342K%	20.5	Switzerland

chevron_leftBack